Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: results from a single-center biopsy study

Eda Kaya,Yusuf Yilmaz

DOI: https://doi.org/10.1097/cm9.0000000000003023

IF: 6.133

2024-03-12

Chinese Medical Journal

Abstract:To the Editor : The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence of steatosis in the absence of other hepatic diseases. However, in recent years, there has been a growing movement to phase out and retire this term. In 2020, Eslam et al [ 1 ] proposed a new definition — metabolic (dysfunction) associated fatty liver disease (MAFLD) — redefining the disease to include hepatic steatosis along with other factors such as diabetes, obesity, overweight, or meeting the criteria for metabolic dysfunction. The transition from NAFLD to MAFLD was deemed necessary for several reasons, including the inability of NAFLD to clearly explain the disease's pathophysiology, the possibility of patient stigma due to the term "alcoholic," potential miscommunication between patient and physician, and a preference for defining the disease by positive diagnostic criteria rather than through exclusion. [ 1 ] Although MAFLD and NAFLD did not correspond to the identical population, there was a high consistency between NAFLD and MAFLD. [ 2 ] The shift in terminology without comprehensive understanding of its implications has also been met with resistance, mainly due to the potential confusion it could cause. In an effort to conclude the ongoing debate, a team of 236 experts from 56 different countries endeavored to pinpoint a new, more appropriate name to supersede the term NAFLD. The consensus reached was to rename the condition as metabolic dysfunction-associated steatotic liver disease (MASLD). The definition of MASLD includes the presence of steatosis paired with a minimum of one of five predetermined cardiometabolic criteria. The existence of cardiometabolic factors in conjunction with secondary etiologies has been categorized separately from MASLD. [ 3 ]

medicine, general & internal